Replies to post #140726 on Biotech Values

[mcbio]

Nplate Sales:

Sales of Nplate® (romiplostim) increased 38 percent to $90 million in the first quarter of 2012 versus $65 million in the first quarter of 2011. These increases were driven primarily by global unit growth.

Presumably good news for LGND and Promacta.